Clearstead Advisors’s Emergent Biosolutions EBS Stock Holding History

Clearstead Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.07K	Buy	+127	New	+$1.06K	﹤0.01%	2667
2026 Q1	–	Sell	-9	Closed	-$112	–	2421
2025 Q4	$112	Sell	9 -176	-95%	-$1.89K	﹤0.01%	2502
2025 Q3	$1.63K	Buy	+185	New	+$1.44K	﹤0.01%	2512
2022 Q4	–	Sell	-400	Closed	-$8K	–	1334
2022 Q3	$8K	Hold	400	–	–	﹤0.01%	915
2022 Q2	$12K	Hold	400	–	–	﹤0.01%	892
2022 Q1	$16K	Hold	400	–	–	﹤0.01%	903
2021 Q4	$17K	Buy	400 +202	+102%	+$9.14K	﹤0.01%	849
2021 Q3	$10K	Buy	+198	New	+$12K	﹤0.01%	941

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Clearstead Advisors's EBS Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Emergent Biosolutions (EBS) in Q2 2026: 127 shares worth $1.07K. The stake represents ﹤0.01% of the portfolio and ranks #2667 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in EBS as recently as Q4 2025.

Clearstead Advisors first reported a position in EBS in Q3 2021 and has held it in 8 quarters since. The position peaked at $17K in Q4 2021. 195 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Clearstead Advisors held 127 shares of Emergent Biosolutions worth $1.07K as of Q2 2026.
Emergent Biosolutions was a new Clearstead Advisors position in Q2 2026.
Emergent Biosolutions made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2667 holding.
Clearstead Advisors first reported a position in Emergent Biosolutions in Q3 2021 and has held it in 8 quarters since.
Clearstead Advisors's Emergent Biosolutions position peaked at $17K in Q4 2021.
195 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.